Direxion Daily South Korea Bull 3X Shares (KORU) Stock
Direxion Daily South Korea Bull 3X Shares Chart
Company Profile
Price: $41.43
Market Cap: $82.77M
Exchange: AMEX
CEO:
Sector: Financial Services
Industry: Asset Management - Leveraged
Employees: -
Headquarters: None, DE
Business Summary
The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, ETFs that track the index, securities of the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is designed to measure the performance of the large- and mid-cap segments of the South Korean equity market, covering approximately 85% of the free float-adjusted market capitalization of South Korean issuers. It is non-diversified.
Direxion Daily South Korea Bull 3X Shares News
KORU: Navigating 2025 Volaility
The Direxion Daily MSCI South Korea Bull 3X Shares aims for 300% daily returns of the MSCI Korea 25/50 Index but is risky as a long term hold. This ETF can yield significant gains during bull runs but can also incur substantial losses during downturns, as seen in Q4 2024. South Korea's stock market has rebounded from December lows but faces economic and political uncertainties, making short-term pullbacks likely.
KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that.
KORU Medical Systems Has A Long Runway
KORU Medical Systems' stock has surged 60% since November, driven by the success of its FREEDOM System for subcutaneous immunoglobulin delivery. The SCIg market is growing rapidly, with KORU outperforming competitors by capturing market share and benefiting from trends like prefilled syringes. Strong international growth, new therapies, and product innovations are key drivers, with significant revenue from recurring patients and promising future launches.
KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunogl.
KORU Medical Systems to Participate in Piper Sandler's 36th Annual Healthcare Conference
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024. KORU Medical's management is scheduled to present at Piper Sandler's 36th Annual Healthcare.
KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end cash guidance. Recent Highlights Third quarter 2024 net revenues of $8.
KORU Medical Systems to Participate in Upcoming Investor Conferences
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences. KORU Medical's management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, Novemb.
Impressive Turnaround At KORU Medical
KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials.
Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion
MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution. “We want to ensure that medications are safe and easy to use for.
KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a collaboration with a global pharmaceutical company to initiate a feasibility study with KORU Medical's Freedom Infusion System (the “Freedom System”) for an FDA and EMA approved subcutaneous onco.
South Korea's Exports Rebound In October 2023
South Korea's exports to mainland China have remained weak during 2023, recording a decline of 9.5% y/y in October. According to latest trade data from South Korea's Ministry of Trade, Industry and Energy, South Korea's merchandise exports showed grew by 5.1% y/y in October 2023.
Korea Likely To See Modest Recovery Through Rest Of Year
We believe that Korea's economy bottomed out in the fourth quarter of last year. However, the recovery will be quite shallow going forward, so GDP growth will remain below potential levels. We forecast the Bank of Korea (BoK) will make its first move to cut its policy rate in the fourth quarter of this year before the easing cycle of other major central banks begins.
South Korea's Economy Faces Rising Headwinds In 2023
The South Korean economy slowed significantly during the second half of 2022, with GDP contracting by 0.4% quarter-on-quarter (q/q) in the fourth quarter of 2022. South Korea's manufacturing sector remained in contraction territory at the start of 2023, according to latest PMI data from S&P Global, as another contraction in new orders drove output volumes down.
The Power Of South Korea's Battery Sector Confirmed
Investor expectations were buoyed at the beginning of the year with the inauguration of pro-business President Yoon Suk-yeol. By 2026, South Korean battery makers will be operating plants in the U.S., accounting for at least 200-gigawatt hours each year.
Direxion Daily South Korea Bull 3X Shares Earnings
This section highlights Direxion Daily South Korea Bull 3X Shares's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Direxion Daily South Korea Bull 3X Shares, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Profit Ratio |
| Research and Development Expenses |
| General and Administrative Expenses |
| Selling and Marketing Expenses |
| Selling General and Administrative Expenses |
| Other Expenses |
| Operating Expenses |
| Cost and Expenses |
| Interest Income |
| Interest Expense |
| Depreciation and Amortization |
| EBITDA |
| EBITDA Ratio |
| Operating Income |
| Operating Income Ratio |
| Total Other Income Expenses Net |
| Income Before Tax |
| Income Before Tax Ratio |
| Income Tax Expense |
| Net Income |
| Net Income Ratio |
| EPS |
| EPS Diluted |
| Weighted Average Shares Outstanding |
| Weighted Average Shares Outstanding Diluted |
| SEC Filing |
Income Statement Charts
| Breakdown |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Profit Ratio |
| Research and Development Expenses |
| General and Administrative Expenses |
| Selling and Marketing Expenses |
| Selling General and Administrative Expenses |
| Other Expenses |
| Operating Expenses |
| Cost and Expenses |
| Interest Income |
| Interest Expense |
| Depreciation and Amortization |
| EBITDA |
| EBITDA Ratio |
| Operating Income |
| Operating Income Ratio |
| Total Other Income Expenses Net |
| Income Before Tax |
| Income Before Tax Ratio |
| Income Tax Expense |
| Net Income |
| Net Income Ratio |
| EPS |
| EPS Diluted |
| Weighted Average Shares Outstanding |
| Weighted Average Shares Outstanding Diluted |
| SEC Filing |
Annual Balance Sheet
| Breakdown |
|---|
| Cash and Cash Equivalents |
| Short Term Investments |
| Cash and Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| Property Plant Equipment Net |
| Goodwill |
| Intangible Assets |
| Goodwill and Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Total Non-Current Assets |
| Other Assets |
| Total Assets |
| Account Payables |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Long Term Debt |
| Deferred Revenue Non-Current |
| Deferred Tax Liabilities Non-Current |
| Other Non-Current Liabilities |
| Total Non-Current Liabilities |
| Other Liabilities |
| Total Liabilities |
| Preferred Stock |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income Loss |
| Other Total Stockholders Equity |
| Total Stockholders Equity |
| Total Equity |
| Total Liabilities and Stockholders Equity |
| Minority Interest |
| Total Liabilities and Total Equity |
| Total Investments |
| Total Debt |
| Net Debt |
Balance Sheet Charts
| Breakdown |
|---|
| Cash and Cash Equivalents |
| Short Term Investments |
| Cash and Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| Property Plant Equipment Net |
| Goodwill |
| Intangible Assets |
| Goodwill and Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Total Non-Current Assets |
| Other Assets |
| Total Assets |
| Account Payables |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Long Term Debt |
| Deferred Revenue Non-Current |
| Deferred Tax Liabilities Non-Current |
| Other Non-Current Liabilities |
| Total Non-Current Liabilities |
| Other Liabilities |
| Total Liabilities |
| Preferred Stock |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income Loss |
| Other Total Stockholders Equity |
| Total Stockholders Equity |
| Total Equity |
| Total Liabilities and Stockholders Equity |
| Minority Interest |
| Total Liabilities and Total Equity |
| Total Investments |
| Total Debt |
| Net Debt |
Annual Cash Flow
| Breakdown |
|---|
| Net Income |
| Depreciation and Amortization |
| Deferred Income Tax |
| Stock Based Compensation |
| Change in Working Capital |
| Accounts Receivables |
| Inventory |
| Accounts Payables |
| Other Working Capital |
| Other Non Cash Items |
| Net Cash Provided by Operating Activities |
| Investments in Property Plant and Equipment |
| Acquisitions Net |
| Purchases of Investments |
| Sales Maturities of Investments |
| Other Investing Activities |
| Net Cash Used for Investing Activities |
| Debt Repayment |
| Common Stock Issued |
| Common Stock Repurchased |
| Dividends Paid |
| Other Financing Activities |
| Net Cash Used Provided by Financing Activities |
| Effect of Forex Changes on Cash |
| Net Change in Cash |
| Cash at End of Period |
| Cash at Beginning of Period |
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
Cash Flow Charts
| Breakdown |
|---|
| Net Income |
| Depreciation and Amortization |
| Deferred Income Tax |
| Stock Based Compensation |
| Change in Working Capital |
| Accounts Receivables |
| Inventory |
| Accounts Payables |
| Other Working Capital |
| Other Non Cash Items |
| Net Cash Provided by Operating Activities |
| Investments in Property Plant and Equipment |
| Acquisitions Net |
| Purchases of Investments |
| Sales Maturities of Investments |
| Other Investing Activities |
| Net Cash Used for Investing Activities |
| Debt Repayment |
| Common Stock Issued |
| Common Stock Repurchased |
| Dividends Paid |
| Other Financing Activities |
| Net Cash Used Provided by Financing Activities |
| Effect of Forex Changes on Cash |
| Net Change in Cash |
| Cash at End of Period |
| Cash at Beginning of Period |
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
Direxion Daily South Korea Bull 3X Shares Dividends
Explore Direxion Daily South Korea Bull 3X Shares's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
x
Direxion Daily South Korea Bull 3X Shares Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.0075 | $0.075 | December 23, 2024 | December 23, 2024 | December 31, 2024 | |
| $0.0154 | $0.154 | September 24, 2024 | September 24, 2024 | October 01, 2024 | January 18, 2024 |
| $0.0024 | $0.02422 | June 25, 2024 | June 25, 2024 | July 02, 2024 | January 18, 2024 |
| $0.0026 | $0.02635 | March 19, 2024 | March 20, 2024 | March 26, 2024 | January 18, 2024 |
| $0.1505 | $1.5054 | December 21, 2023 | December 22, 2023 | December 29, 2023 | March 23, 2023 |
| $0.0149 | $0.1489 | September 19, 2023 | September 20, 2023 | September 26, 2023 | March 23, 2023 |
| $0.0314 | $0.3135 | June 21, 2023 | June 22, 2023 | June 28, 2023 | March 23, 2023 |
| $0.0427 | $0.4271 | March 21, 2023 | March 22, 2023 | March 28, 2023 | March 20, 2023 |
| $0.0036 | $0.03624 | December 20, 2022 | December 21, 2022 | December 28, 2022 | February 04, 2022 |
| $0.191 | $1.9082 | December 21, 2021 | December 22, 2021 | December 29, 2021 | December 20, 2021 |
| $0.003 | $0.0312 | December 22, 2020 | December 23, 2020 | December 30, 2020 | January 09, 2020 |
| $0.19 | $1.8996 | December 23, 2019 | December 24, 2019 | December 31, 2019 | March 13, 2019 |
| $0.024 | $0.241 | September 24, 2019 | September 25, 2019 | October 01, 2019 | March 13, 2019 |
| $0.027 | $0.2739 | June 25, 2019 | June 26, 2019 | July 02, 2019 | March 13, 2019 |
| $0.138 | $1.3844 | December 27, 2018 | December 28, 2018 | January 04, 2019 | December 24, 2018 |
| $0.0207 | $0.207 | March 20, 2018 | March 21, 2018 | March 27, 2018 | January 18, 2018 |
| $0.394 | $3.94 | December 19, 2017 | December 20, 2017 | December 27, 2017 | |
| $0.184 | $1.84 | December 13, 2017 | December 14, 2017 | December 20, 2017 | |
| $0.1135 | $1.135 | December 12, 2013 |
Peers: Asset Management - Leveraged
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Direxion Daily FTSE Europe Bull 3X Shares
EURL
|
$24.95M | $27.61 | $ | $ | $ |
Direxion Daily MSCI India Bull 2X Shares
INDL
|
$67.93M | $49.68 | $ | $ | $ |
Direxion Daily MSCI Mexico Bull 3X Shares
MEXX
|
$18.42M | $11.27 | $ | $ | $ |
Direxion Daily Mid Cap Bull 3X Shares
MIDU
|
$81.26M | $39.27 | $ | $ | $ |
Direxion Daily MSCI Brazil Bull 2X Shares
BRZU
|
$123.54M | $49.23 | $ | $ | $ |
Related Metrics
Explore detailed financial metrics and analysis for KORU.